Observations placeholder
Neupro
Identifier
019685
Type of Spiritual Experience
Background
A description of the experience
Rotigotine (Neupro) is a dopamine agonist of the non-ergoline class of medications indicated for the treatment of Parkinson's disease (PD) and Willis-Ekbom Disease (WED) formerly known as restless legs syndrome (RLS) in Europe and the United States It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours
Like other dopamine agonists, rotigotine has been used off label in the treatment of depression as well.
Side effects
General side effects for rotigotine may include constipation, dyskinesia, nausea, vomiting, dizziness, fatigue, insomnia, somnolence, confusion, and hallucinations. More serious complications can include psychosis and impulse control disorders like hypersexuality, punding, and pathological gambling. Mild adverse skin reactions at the patch application site may also occur.
On Dec, 27, 2016 2,945 people reported to have side effects when taking Neupro.
Among them, 139 people (4.72%) have Hallucination
Time on Neupro when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 43.64% | 41.82% | 12.73% | 1.82% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Neupro :
Female | Male | |
Hallucination | 24.04% | 75.96% |
Age of people who have Hallucination when taking Neupro :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.56% | 16.67% | 80.77% |
On Jan, 2, 2016: 1,541 people reported to have side effects when taking Neupro. Among them, 28 people (1.82%) have Death.
Time on Neupro when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Neupro :
Female | Male | |
Death | 17.24% | 82.76% |